Last updated: September 5, 2026
Fosaprepitant dimeglumine is the intravenous prodrug of aprepitant, marketed originally by Merck as Emend for Injection. The product is an established neurokinin-1, or NK1, receptor antagonist used with other antiemetics to prevent chemotherapy-induced nausea and vomiting. Its commercial trajectory has shifted from branded innovation to mature, multisource injectable competition.
The central market factors are generic entry, hospital purchasing pressure, substitution with oral aprepitant and fixed-dose antiemetic regimens, and the limited financial disclosure available for the individual product. Merck reports Emend within broader product categories and does not separately disclose current fosaprepitant dimeglumine revenue in its public filings.[1]
What is fosaprepitant dimeglumine and how is it used?
Fosaprepitant dimeglumine is a water-soluble phosphorylated prodrug that converts rapidly to aprepitant after intravenous administration. Aprepitant blocks the NK1 receptor and substance P signaling, which is important in delayed chemotherapy-induced nausea and vomiting.
The U.S. approved product is Emend for Injection, supplied as a lyophilized formulation for reconstitution. The labeled indications include:
- Highly emetogenic cancer chemotherapy, including high-dose cisplatin regimens.
- Moderately emetogenic chemotherapy.
- Use in combination with a corticosteroid and a 5-HT3 antagonist.
- Prevention of acute and delayed chemotherapy-induced nausea and vomiting.
The product is administered before chemotherapy, generally as a single intravenous dose. The injectable formulation has clinical value when oral administration is impractical, when patients cannot swallow, or when infusion-center protocols favor intravenous administration.
FDA regulatory status
| Regulatory item |
Detail |
| Active ingredient |
Fosaprepitant dimeglumine |
| Pharmacologic class |
NK1 receptor antagonist prodrug |
| Reference product |
Emend for Injection |
| Original sponsor |
Merck & Co. |
| U.S. application |
NDA 022023 |
| FDA approval |
2008 |
| Primary indication |
Prevention of chemotherapy-induced nausea and vomiting |
| Dosage form |
Intravenous injection, reconstituted from lyophilized powder |
| Regulatory pathway for competitors |
ANDA generic approval |
| Biologic status |
Not a biologic; biosimilar pathway does not apply |
Fosaprepitant is not a biosimilar product and does not face biosimilar substitution. Competitive entry occurs through abbreviated new drug applications, therapeutic substitution, hospital formulary decisions, and competition from oral aprepitant and other antiemetic products.
How large is the fosaprepitant dimeglumine market?
The U.S. market is mature and fragmented. The branded market has contracted as generic fosaprepitant products entered and hospitals adopted lower-cost alternatives.
The addressable market consists primarily of:
- Hospital outpatient infusion centers.
- Academic cancer centers.
- Community oncology practices.
- Specialty pharmacies and institutional distributors.
- International oncology markets using intravenous NK1 antagonists.
Demand is linked to chemotherapy volume, regimen mix, antiemetic guidelines, and the proportion of patients receiving highly or moderately emetogenic chemotherapy. It is not directly linked to the total oncology drug market because only a subset of chemotherapy regimens requires NK1 prophylaxis.
Key market drivers
- Continued use of platinum-based and other highly emetogenic chemotherapy.
- Preference for single-dose intravenous prophylaxis in infusion settings.
- Growth in outpatient oncology treatment.
- Protocol-based prescribing and standing orders.
- Generic price competition.
- Substitution by oral aprepitant, netupitant/palonosetron, and olanzapine-containing regimens.
- Hospital group purchasing organization negotiations.
Key market constraints
- Generic fosaprepitant availability.
- Low switching costs at the institutional level.
- Limited differentiation after loss of core exclusivity.
- Increasing use of multi-drug antiemetic protocols.
- Budget pressure on supportive-care products.
- Alternative intravenous NK1 antagonists, including rolapitant injection in markets where available.
What patents protect fosaprepitant dimeglumine?
The original intellectual-property estate covered aprepitant chemistry, prodrug technology, pharmaceutical compositions, and methods of preventing chemotherapy-induced nausea and vomiting. The relevant protection was broader than the final commercial product because it included the active parent molecule and related prodrug and formulation concepts.
Core patent protection for the Emend franchise has expired or reached the end of its commercial life in the United States. The Orange Book remains the primary source for product-specific listed patents and exclusivity information.[2]
Patent categories
| Patent category |
Commercial relevance |
| Aprepitant compound patents |
Protected the active NK1 antagonist and supported the oral Emend franchise |
| Fosaprepitant prodrug patents |
Covered phosphorylated prodrug chemistry and conversion to aprepitant |
| Pharmaceutical-composition patents |
Addressed injectable compositions, excipients, and stability |
| Method-of-use patents |
Covered prevention of chemotherapy-induced nausea and vomiting |
| Manufacturing patents |
May protect synthesis, purification, crystallization, or formulation processes |
| Pediatric exclusivity |
Could extend listed protection by six months when granted |
The highest-value protection was the compound and clinical-use estate. Formulation and manufacturing patents became more important after core compound protection weakened, but those patents generally provided narrower barriers and were more vulnerable to design-around strategies.
When did fosaprepitant lose exclusivity?
Fosaprepitant dimeglumine lost effective U.S. market exclusivity in stages rather than on a single date. The relevant sequence involved expiration of the original aprepitant estate, expiration or weakening of prodrug and formulation protection, and subsequent approval of generic injectable products.
The product’s commercial exclusivity was also affected by the distinction between:
- Patent expiration.
- FDA regulatory exclusivity.
- Approval of the first ANDA.
- Commercial launch by generic manufacturers.
- Hospital conversion to generic purchasing.
For a mature injectable product, the first generic launch usually creates a rapid price decline because institutional buyers can switch at the formulary or wholesaler level. The precise erosion rate depends on the number of approved suppliers and supply reliability.
Exclusivity timeline
| Period |
Market event |
| 2008 |
FDA approval of Emend for Injection |
| 2010s |
Expansion of intravenous antiemetic use and Merck commercial penetration |
| Late 2010s |
Generic fosaprepitant approvals and increasing price pressure |
| 2020 onward |
Mature multisource market with branded-product erosion |
| Current market phase |
Generic and hospital-contracting market; limited standalone brand growth |
The product is no longer protected by a meaningful period of U.S. market exclusivity comparable to a newly launched oncology supportive-care product.
What is the Orange Book status of fosaprepitant dimeglumine?
The Orange Book identifies Emend for Injection as the reference listed drug against which approved ANDA products may be compared. Orange Book-listed patents and exclusivity codes determine whether an ANDA applicant must make a Paragraph IV certification or may file based on an expiration-date certification.[2]
Because the commercial protection has matured, the main Orange Book issue is no longer whether the reference product can block broad generic entry. The relevant questions are whether any remaining listed patent covers a specific dosage strength or formulation and whether a generic applicant can certify noninfringement or invalidity.
Paragraph IV challenges
Paragraph IV certification allows an ANDA applicant to assert that a listed patent is invalid, unenforceable, or not infringed. A Paragraph IV filing can trigger patent litigation and a potential 30-month stay of ANDA approval under the Hatch-Waxman Act.
For fosaprepitant, Paragraph IV risk was most commercially important before broad generic entry. Once multiple injectable generics were approved, the strategic value of defending narrow remaining patents declined unless the patent covered a commercially important formulation or manufacturing feature.
The principal litigation risks for generic applicants were:
- Infringement allegations involving prodrug composition claims.
- Patent claims covering injectable formulations.
- Process claims relating to synthesis or purification.
- Claims directed to dosage and administration schedules.
- Orange Book listing disputes.
Which companies compete with fosaprepitant dimeglumine?
Competition occurs across molecules, dosage forms, and treatment protocols.
| Competitor |
Type |
Competitive position |
| Generic fosaprepitant injection |
Direct generic |
Closest substitute; competes primarily on price and supply |
| Emend for Injection |
Branded reference product |
Retains clinical familiarity but has limited pricing power |
| Oral aprepitant |
Same pharmacologic pathway |
Avoids intravenous administration when oral dosing is feasible |
| Netupitant/palonosetron |
Fixed-dose oral combination |
Competes through regimen simplification |
| Rolapitant |
NK1 antagonist |
Alternative NK1 option, depending on market availability |
| Olanzapine-based regimens |
Different pharmacologic approach |
Increasingly relevant in guideline-driven antiemetic protocols |
| Palonosetron and other 5-HT3 antagonists |
Adjunct or partial substitute |
Usually used with, rather than fully replacing, NK1 therapy |
The strongest direct competition comes from generic fosaprepitant. The strongest indirect competition comes from oral or fixed-dose antiemetic regimens that eliminate the need for an intravenous NK1 product.
How has the financial trajectory developed?
Merck’s Emend franchise generated substantial revenue during its branded growth phase, but public filings do not provide a current standalone revenue series for fosaprepitant dimeglumine. Merck has historically reported Emend within broader product disclosures, and the company’s reporting structure has changed as the franchise matured.[1]
Financial trajectory by phase
Branded expansion
The initial commercial phase benefited from:
- Strong oncology-supportive-care demand.
- Limited competition in the NK1 class.
- High value placed on preventing delayed nausea and vomiting.
- Use in institutional chemotherapy protocols.
- Merck’s established oncology sales infrastructure.
Patent and generic erosion
Revenue pressure increased as:
- Generic aprepitant became available.
- Generic fosaprepitant entered the injectable market.
- Hospitals negotiated multisource contracts.
- Treatment protocols incorporated lower-cost alternatives.
- Physicians gained experience with generic products.
Mature market
The current financial model is based on volume, contract access, and supply reliability rather than premium pricing. Generic manufacturers can still generate attractive returns if they have:
- Reliable sterile injectable production.
- FDA-compliant manufacturing capacity.
- Wholesaler and group purchasing organization access.
- Low defect and shortage rates.
- A cost-efficient supply chain for active pharmaceutical ingredient and fill-finish operations.
The reference brand faces a structurally weaker position because clinical differentiation is limited after generic approval. A branded product may retain residual demand in accounts that value continuity, established procurement, or specific formulation characteristics, but those factors rarely support historical branded pricing.
What manufacturing and intellectual-property barriers remain?
Sterile injectable manufacturing is the primary practical barrier. Chemical synthesis of fosaprepitant is only one part of the competitive equation. Generic suppliers must also validate:
- Sterile processing.
- Aseptic filling.
- Lyophilization.
- Reconstitution performance.
- Particulate and impurity control.
- Container-closure integrity.
- Stability through distribution.
- Compatibility with clinical administration systems.
These requirements can limit the number of reliable suppliers even when patent barriers are weak. Injectable shortages can temporarily improve pricing for manufacturers with available inventory, while quality failures can rapidly remove a supplier from hospital formularies.
Manufacturing patents may still matter if they cover a difficult synthetic intermediate, a specific crystalline form, or a commercially efficient purification route. Their value is narrower than that of a composition-of-matter patent because competitors may use alternative processes.
What generic launch scenarios exist?
Base case: continued price erosion
Multiple suppliers maintain supply, hospital buyers use competitive contracting, and average selling prices decline. Volume remains tied to chemotherapy utilization, but branded revenue continues to shrink.
Tight-supply case: temporary pricing recovery
A manufacturing interruption, regulatory action, or active pharmaceutical ingredient shortage reduces supplier availability. Remaining manufacturers gain short-term negotiating leverage. This scenario affects injectable products more sharply than oral solid products.
Protocol-substitution case: volume decline
Cancer centers shift toward oral NK1 combinations, olanzapine-containing protocols, or fixed-dose products. Fosaprepitant retains use where intravenous administration is operationally preferred but loses share of the broader antiemetic market.
Consolidation case: fewer viable suppliers
Low margins and sterile-manufacturing costs cause some generic companies to exit. The market becomes less competitive, with greater sensitivity to supply disruptions and contracting cycles.
How strong is the fosaprepitant patent estate?
The estate was strong during the original Emend commercialization period because it combined active-molecule, prodrug, method-of-use, and formulation protection. Its present strength is low from a market-exclusivity perspective because core protection has expired and the product is exposed to generic competition.
| Patent-estate factor |
Current assessment |
| Composition-of-matter protection |
Expired or commercially exhausted |
| Prodrug protection |
Limited current blocking power |
| Method-of-use protection |
Narrower and less effective against routine generic entry |
| Formulation protection |
Potentially relevant to specific products, but design-around risk is high |
| Manufacturing protection |
May protect process efficiencies, not the market broadly |
| Litigation leverage |
Low compared with the branded launch period |
| Generic entry barrier |
Primarily manufacturing and supply execution |
What litigation and settlement issues affect the market?
The principal legal pathway is Hatch-Waxman litigation associated with ANDA filings and Paragraph IV certifications. The economic importance of any settlement depends on the remaining patent term, the number of competing ANDAs, and the commercial value of delayed entry.
At the current market stage, settlement agreements are less likely to preserve material branded revenue than they would have before generic fosaprepitant approval. Any remaining dispute would more likely concern a specific formulation, process, or product presentation than broad control of the intravenous NK1 market.
Key Takeaways
- Fosaprepitant dimeglumine is the intravenous prodrug of aprepitant and is used to prevent chemotherapy-induced nausea and vomiting.
- Emend for Injection was FDA-approved in 2008 under NDA 022023.
- The U.S. market has transitioned from branded exclusivity to generic injectable competition.
- Merck does not separately disclose current fosaprepitant revenue, limiting product-level financial precision.
- Generic competition, hospital contracting, oral aprepitant, and alternative antiemetic regimens drive current market dynamics.
- Biosimilar risk does not apply because fosaprepitant is a small-molecule drug, not a biologic.
- The strongest remaining barriers are sterile injectable manufacturing, supply reliability, regulatory compliance, and contracting access.
- Current patent strength is materially weaker than during the original Emend launch period.
- Revenue exposure is concentrated in the mature supportive-care market and is vulnerable to price erosion and protocol substitution.
FAQs About Fosaprepitant Dimeglumine
Is fosaprepitant dimeglumine still a branded drug?
The original branded product is Emend for Injection, but the market includes approved generic fosaprepitant products. Brand demand is constrained by institutional purchasing and generic substitution.
Does fosaprepitant have biosimilar competition?
No. Biosimilars apply to biologic products. Fosaprepitant is a chemically synthesized small-molecule drug and competes through the ANDA generic pathway.
Is fosaprepitant the same as aprepitant?
Fosaprepitant is an intravenous prodrug that converts to aprepitant. Aprepitant is also available as an oral drug, while fosaprepitant is used primarily by intravenous administration.
What is the main commercial risk for fosaprepitant manufacturers?
The main risks are price compression, hospital-contract loss, sterile manufacturing failures, regulatory observations, and substitution by oral or fixed-dose antiemetic regimens.
Can a generic manufacturer still earn attractive returns?
Yes, but returns depend on manufacturing efficiency, supply reliability, contract access, and the number of active competitors. Injectable shortages can improve pricing temporarily, while excess capacity can make the market unattractive.
References
-
Merck & Co., Inc. (2024). 2023 annual report. https://www.merck.com/investor-relations/financial-information/annual-reports/
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
-
National Comprehensive Cancer Network. (2024). NCCN clinical practice guidelines in oncology: Antiemesis. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1429
-
U.S. Food and Drug Administration. (2008). Emend for injection prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022023lbl.pdf
